The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
Open accessAbstract
Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide and has a very poor prognosis. Its occurrence has been on the increase in recent years. Surgical resection and liver transplantation are the primary methods of treatment for HCC patients, but can only be applied to 15% of patients. The median survival time of unresectable or metastasizing HCC patients is only a few months. Existing systemic treatment methods are not effective for advanced HCC patients and a new method of treatment is needed for these patients. It has been established that the HCC occurs in multiple stages, however, the pathogenesis at a molecular level is not clear and many key factors are yet to be determined. In the past 30 years, it has become evident that the Ras/Raf/MEK/extracellular signal-regulated kinase (ERK) signaling pathway plays a significant role in the occurrence and development of HCC. This review focused on the association between the Ras/Raf/MEK/ERK signaling pathway and HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284
Jordan, C. T., Guzman, M. L., & Noble, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra061808 · Cited by 1,702
Phosphorylation of c-jun mediated by MAP kinases
Pulverer, B. J., Kyriakis, J. M., Avruch, J., Nikolakaki, E., & Woodgett, J. R. (1991) · Nature · doi:10.1038/353670a0 · Cited by 1,468
The c-fos protein interacts with c-JunAP-1 to stimulate transcription of AP-1 responsive genes
Chiu, R., Boyle, W. J., Meek, J., Smeal, T., Hunter, T., & Karin, M. (1988) · Cell · doi:10.1016/0092-8674(88)90076-1 · Cited by 1,335
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain
Marais, R., Wynne, J., & Treisman, R. (1993) · Cell · doi:10.1016/0092-8674(93)90237-k · Cited by 1,275
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
Garnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
ERK implication in cell cycle regulation
Chambard, J.-C., Lefloch, R., Pouysségur, J., & Lenormand, P. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.11.010 · Cited by 750
Signalling, cell cycle and pluripotency in embryonic stem cells
Burdon, T., Smith, A., & Savatier, P. (2002) · Trends in Cell Biology · doi:10.1016/s0962-8924(02)02352-8 · Cited by 711
Hoshino, R., Chatani, Y., Yamori, T., Tsuruo, T., Oka, H., Yoshida, O., Shimada, Y., Ari-i, S., Wada, H., Fujimoto, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202367 · Cited by 691
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis
Steelman, L. S., Pohnert, S. C., Shelton, J. G., Franklin, R. A., Bertrand, F. E., & McCubrey, J. A. (2004) · Leukemia · doi:10.1038/sj.leu.2403241 · Cited by 684
Lenormand, P., Sardet, C., Pagès, G., L'Allemain, G., Brunet, A., & Pouysségur, J. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.5.1079 · Cited by 661
Rinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.185 · Cited by 645
Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1.
Alessi, D. R., Saito, Y., Campbell, D. G., Cohen, P., Sithanandam, G., Rapp, U., Ashworth, A., Marshall, C. J., & Cowley, S. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06424.x · Cited by 559
Nakano, H., Shindo, M., Sakon, S., Nishinaka, S., Mihara, M., Yagita, H., & Okumura, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3537 · Cited by 517
Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510
Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase
Yan, J., Roy, S., Apolloni, A., Lane, A., & Hancock, J. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.24052 · Cited by 477
American Society of Clinical Oncology educational book
Perry, M. C. (2003) · Medical Entomology and Zoology · Cited by 471
Hyperexpression of mitogen-activated protein kinase in human breast cancer.
Sivaraman, V. S., Wang, H., Nuovo, G. J., & Malbon, C. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119309 · Cited by 451
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
Stirewalt, D. L., Kopecky, K. J., Meshinchi, S., Appelbaum, F. R., Slovak, M. L., Willman, C. L., & Radich, J. P. (2001) · Blood · doi:10.1182/blood.v97.11.3589 · Cited by 431
Regulation and Role of Raf-1/B-Raf Heterodimerization
Rushworth, L. K., Hindley, A. D., O'Neill, E., & Kolch, W. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2262-2272.2006 · Cited by 418
Ray, R. B., Lagging, L. M., Meyer, K., & Ray, R. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4438-4443.1996 · Cited by 403
Ebara, M., Ohto, M., Shinagawa, T., Sugiura, N., Kimura, K., Matsutani, S., Morita, M., Saisho, H., Tsuchiya, Y., & Okuda, K. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90923-6 · Cited by 394
Friday, B. B., & Adjei, A. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4790 · Cited by 374
Ito, Y., Sasaki, Y., Horimoto, M., Wada, S., Tanaka, Y., Kasahara, A., Ueki, T., Hirano, T., Yamamoto, H., Fujimoto, J., et al. (1998) · Hepatology · doi:10.1002/hep.510270409 · Cited by 334
Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma.
Nishida, N., Fukuda, Y., Komeda, T., Kita, R., Sando, T., Furukawa, M., Amenomori, M., Shibagaki, I., Nakao, K., & Ikenaga, M. (1994) · PubMed · Cited by 330
Doria, M., Klein, N. P., Lucito, R., & Schneider, R. J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00156.x · Cited by 313
Inducible regulatory elements in the human cyclin D1 promoter.
Herber, B., Truss, M., Beato, M., & Müller, R. (1994) · PubMed · Cited by 309
Schmitz, K. J., Wohlschlaeger, J., Lang, H., Sotiropoulos, G. C., Malago, M., Steveling, K., Reis, H., Cicinnati, V. R., Schmid, K. W., & Baba, H. A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.08.018 · Cited by 309
伊藤, 善. (1998) · doi:10.11501/3155565 · Cited by 300
Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma.
Oka, H., Chatani, Y., Hoshino, R., Ogawa, O., Kakehi, Y., Terachi, T., Okada, Y., Kawaichi, M., Kohno, M., & Yoshida, O. (1995) · PubMed · Cited by 299
Huynh, H., Nguyen, T. T. T., Chow, K.-H. K.-P., Tan, P. H., Soo, K. C., & Tran, E. (2003) · BMC Gastroenterology · doi:10.1186/1471-230x-3-19 · Cited by 289
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas
Fransen, K. (2003) · Carcinogenesis · doi:10.1093/carcin/bgh049 · Cited by 268
Llovet, J. M., Bruix, J., & Gores, G. J. (2000) · Hepatology · doi:10.1053/he.2000.6959 · Cited by 180
Kortenjann, M., Thomae, O., & Shaw, P. E. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4815 · Cited by 179
Yoshida, T., Hisamoto, T., Akiba, J., Koga, H., Nakamura, K., Tokunaga, Y., Hanada, S., Kumemura, H., Maeyama, M., Harada, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209635 · Cited by 169
Involvement of the p38 mitogen‐activated protein kinase cascade in hepatocellular carcinoma
Iyoda, K., Sasaki, Y., Horimoto, M., Toyama, T., Yakushijin, T., Sakakibara, M., Takehara, T., Fujimoto, J., Hori, M., Wands, J. R., et al. (2003) · Cancer · doi:10.1002/cncr.11425 · Cited by 152
Zhang, Z., Zhou, X., Shen, H., Wang, D., & Wang, Y. (2009) · BMC Medicine · doi:10.1186/1741-7015-7-41 · Cited by 150
Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma*1
Hwang, Y. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.02.009 · Cited by 143
Tanaka, S., & Wands, J. R. (1996) · PubMed · Cited by 122
Overexpression of cyclin D1 enhances gene amplification.
Zhou, P., Jiang, W. B., Weghorst, C. M., & Weinstein, I. B. (1996) · PubMed · Cited by 111
Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development
Chung, E., & Kondo, M. (2010) · Immunologic Research · doi:10.1007/s12026-010-8187-5 · Cited by 107
Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma1
Wiesenauer, C. A., Yip-Schneider, M., Wang, Y., & Schmidt, C. M. (2004) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2003.10.004 · Cited by 101
Analysis of BRAF Mutation in Primary and Metastatic Melanoma
Libra, M., Malaponte, G., Navolanic, P. M., et al. (2005) · Cell Cycle · doi:10.4161/cc.4.10.2026 · Cited by 100
Tsukada, Y.-I., Miyazawa, K., & Kitamura, N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010890200 · Cited by 89
Ito, T., Sasaki, Y., & Wands, J. R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.943 · Cited by 89
Sato, Y., Kato, J., Takimoto, R., Takada, K., Kawano, Y., Miyanishi, K., Kobune, M., Sato, Y., Takayama, T., Matunaga, T., et al. (2006) · Gut · doi:10.1136/gut.2005.070417 · Cited by 88
[Epidemiology and risk factors of hepatocellular carcinoma].
Budny, A., Kozłowski, P., Kamińska, M., Jankiewicz, M., Kolak, A., Kukiełka-Budny, B., Budny, W., Niemunis-Sawicka, J., Szczypiór, G., Kurniawka, B., et al. (2017) · PubMed · Cited by 79
Blalock, W. L., Pearce, M., Steelman, L. S., Franklin, R. A., McCarthy, S. A., Cherwinski, H. M., McMahon, M., & McCubrey, J. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203337 · Cited by 75
The Effects of a Novel MEK Inhibitor PD184161 on MEK-ERK Signaling and Growth in Human Liver Cancer
Klein, P. J., Schmidt, C. M., Wiesenauer, C. A., Choi, J. N., Gage, E. A., Yip-Schneider, M., Wiebke, E. A., Wang, Y., Omer, C. A., & Sebolt, J. S. (2006) · Neoplasia · doi:10.1593/neo.05373 · Cited by 73
Liver Cancer Working Group Report
Kudo, M., Han, K., Kokudo, N., Cheng, A., Choi, B. I., Furuse, J., Izumi, N., Park, J.-W., Poon, R. T. P., & Sakamoto, M. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq123 · Cited by 72
Peyssonnaux, C., Provot, S., Felder‐Schmittbuhl, M., Calothy, G., & Eychène, A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.19.7068-7079.2000 · Cited by 62
Leyton, J., Smith, G. S. T., Lees, M., Perumal, M., Nguyen, Q., Aigbirhio, F. I., Golovko, O., He, Q., Workman, P., & Aboagye, E. O. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0264 · Cited by 47
Role of Matrix, Fibroblasts and Type IV Collagenases in Tumor Progression and Invasion
Noël, A., Emonard, H., Polette, M., Birembaut, P., & Foidart, J. M. (1994) · Pathology - Research and Practice · doi:10.1016/s0344-0338(11)80999-4 · Cited by 42
Kortenjann, M., Thomae, O., & Shaw, P. E. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4815-4824.1994 · Cited by 42
Kitahara, T., Kiryu‐Seo, S., Ohno, K., Morita, N., Kubo, T., & Kiyama, H. (1994) · Neuroscience Research · doi:10.1016/0168-0102(94)90097-3 · Cited by 30
Epidemiology and Risk Factors of Hepatocellular Carcinoma
El‐Serag, H. B., Balakrishnan, M., & Natarajan, Y. (2024) · Wiley eBooks · doi:10.1002/9781119756422.ch14 · Cited by 14
Cited by
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
Cancer Cells Tune the Signaling Pathways to Empower de Novo Synthesis of Nucleotides
Villa, E., Ali, E., Sahu, U., & Ben-Sahra, I. (2019) · Cancers · doi:10.3390/cancers11050688 · Cited by 281
Zhang, R., Ma, M., Lin, X.-H., Liu, H.-H., Chen, J., Chen, J., Gao, D.-M., Cui, J.-F., Ren, Z.-G., & Chen, R.-X. (2018) · BMC Cancer · doi:10.1186/s12885-018-4820-9 · Cited by 68
Metadata
- Authors
- Li, L., Zhao, G.-D., Shi, Z., Qi, L.-L., Zhou, L.-Y., & Fu, Z.-X.
- Venue
- Oncology Letters
- Publisher
- Spandidos Publications
- Published
- 2016-09-09
- Volume
- 12
- Issue
- 5
- Pages
- 3045-3050
- ISSN
- 1792-1074 (ISSN-L)
- 1792-1082
- OpenAlex
- W2507610324
- Cited by
- 305
- References
- 62
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.